KALA BIO, Inc. (KALA) income statement
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.26−0.17 (-4.96%)
Close on Nov 18, 2026Market cap $63.05MP/E –Yield –
KALA BIO, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -279.2%
Financial strength
- Current ratio
- 6.88
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 14.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.97
- Dividend yield
- –
See a number that looks wrong?